Skip to main content
NEWLAND PHARMACEUTICAL CO., LTD logo

NEWLAND PHARMACEUTICAL CO., LTD — Investor Relations & Filings

Ticker · 301277 ISIN · CNE1000065K2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 481 across all filing types
Latest filing 2024-03-25 Investor Presentation
Country CN China
Listing Shenzhen Stock Exchange 301277

About NEWLAND PHARMACEUTICAL CO., LTD

https://www.newlandpharma.com

Newland Pharmaceutical Co., Ltd. is a specialized enterprise engaged in the research, development, manufacturing, and global distribution of active pharmaceutical ingredients (APIs) and high-quality chemical intermediates. The company focuses on a broad spectrum of therapeutic categories, including cardiovascular, anti-infective, and metabolic health solutions. Operating with a commitment to rigorous quality control, its production facilities are designed to meet international Good Manufacturing Practice (GMP) standards. Newland Pharmaceutical prioritizes technological innovation and chemical synthesis optimization to deliver reliable pharmaceutical components. Its core operations involve the large-scale production of complex molecules, supporting the supply chains of healthcare providers and pharmaceutical formulators worldwide through a focus on technical excellence and regulatory compliance.

Recent filings

Filing Released Lang Actions
关于举办2023年度业绩网上说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling of a 2023 annual performance online briefing (业绩网上说明会) by the company 新天地药业股份有限公司. It references that the 2023 Annual Report has already been disclosed on March 26, 2024, and provides details for investors to participate in the online meeting to discuss the company's performance. The document does not contain the actual annual report or financial data but rather announces the event for discussing the annual results. The document length is short (1213 characters), and it serves as a notice for an investor presentation event rather than the report itself. Therefore, it fits best under Investor Presentation (IP).
2024-03-25 Chinese
2023年度财务决算报告
Annual Report Classification · 95% confidence The document is titled as the 2023 annual financial settlement report of 新天地药业股份有限公司, containing detailed financial data for the year 2023 including income, profit, cash flow, assets, liabilities, and equity analysis. It mentions that the financial report has been audited by an accounting firm with an unqualified opinion. The content includes comprehensive financial statements and management discussion of financial results and business performance for the full fiscal year 2023. The length of the document (5302 characters) and the detailed financial data confirm it is the actual annual report rather than an announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K). FY 2023
2024-03-25 Chinese
华泰联合证券有限责任公司关于新天地药业股份有限公司2023年年度跟踪报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2023 Annual Tracking Report" by the sponsor (华泰联合证券有限责任公司) for the company 新天地药业股份有限公司. It includes detailed sections on sponsor work overview, company issues and measures, shareholder commitments, major contract performance, and other matters. The content is comprehensive and specific to the sponsor's ongoing monitoring and review of the company during the year 2023. It is not a full annual report (10-K) of the company itself, nor is it a simple announcement or certification. It is a detailed report related to the sponsor's tracking and supervision activities, which aligns with the nature of an Audit Report / Information (AR) category, as it involves review, audit, and supervisory information rather than the company's own financial statements or management discussion. The document length (4524 characters) is sufficient to contain substantive content, not just an announcement. Therefore, the best fit is Audit Report / Information (AR). FY 2023
2024-03-25 Chinese
非经营性资金占用及其他关联资金往来情况汇总表
Regulatory Filings Classification · 95% confidence The document is a summary table detailing non-operating fund occupation and other related party fund transactions for the year 2023, approved by the company's board meeting in March 2024. It contains specific financial data related to related party transactions and fund usage, but it is not a full annual or interim financial report. It is a regulatory disclosure related to related party transactions and fund usage, which does not fit into categories like Annual Report, Interim Report, or Earnings Release. The document is relatively short (3311 characters) and is a detailed tabular disclosure rather than a report or announcement of a report. This type of document is best classified under Regulatory Filings (RNS), as it is a compliance disclosure that does not fit other specific categories.
2024-03-25 Chinese
关于公司及控股子公司使用部分闲置自有资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from the company New Sky Pharmaceutical Co., Ltd. regarding the use of idle self-owned funds for cash management. It details the board meeting resolution, the purpose, amount, duration, and implementation of the cash management plan. It also mentions that the proposal requires shareholder approval to take effect. The document is relatively short (1359 characters) and primarily serves as a formal announcement of a board decision and related opinions, rather than a detailed financial report or regulatory filing. It does not contain financial statements or detailed financial data. Therefore, it fits best under Capital/Financing Update (CAP), as it relates to the company's financing activities and capital management.
2024-03-25 Chinese
2023年度独立董事述职报告(贾发亮)
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2023 from a company. It details the independent director's duties, attendance at board and shareholder meetings, opinions on various company matters, committee participation, and overall evaluation and suggestions. The content focuses on the independent director's report on their activities and oversight during the year, rather than presenting full financial statements or audit results. It is a specialized report related to board/management information, specifically the independent director's annual work report. It is not an annual report (10-K), audit report (AR), or other financial filings. Therefore, the best fitting category is Board/Management Information (MANG). The document length (7108 characters) supports it being a full report rather than a brief announcement or certification.
2024-03-25 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.